FDA Approves Abrysvo for Adults 18-59 at Increased Risk for RSV

Featured News
A needle withdraws the vaccine in an RSV vial.

Abrysvo, Pfizer's respiratory syncytial virus (RSV), has been approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in people 18 to 59 years of age. Our Deputy Director, Dr. Elissa Malkin, led a clinical site that participated in a pivotal phase 3 MONET clinical trail that contributed data to this impactful study. This vaccine is the first RSV vaccine approved for adults younger than 50 years of age and is crucial for at-risk individuals in this age-group.

(image from Getty images)

Click here to read the full article
Respiratory viruses
vaccine

Latest News

Lassa Virus under a microscope
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
An omicron COVID virus. A gray virus with red and orange projections.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…
This is an HIV antibody with a yellow core and pink outer shell.
Targeting HIV broadly neutralizing antibody precursors with precision in humans.
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…